Marshall Wace North America L.P. purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 41,269 shares of the company’s stock, valued at approximately $2,517,000. Marshall Wace North America L.P. owned about 0.08% of LivaNova PLC as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. FMR LLC lifted its stake in LivaNova PLC by 74.9% during the first quarter. FMR LLC now owns 4,817,815 shares of the company’s stock worth $236,118,000 after purchasing an additional 2,063,196 shares during the last quarter. BlackRock Inc. lifted its stake in LivaNova PLC by 16,157.4% during the first quarter. BlackRock Inc. now owns 2,592,889 shares of the company’s stock worth $127,077,000 after purchasing an additional 2,576,940 shares during the last quarter. State Street Corp lifted its stake in LivaNova PLC by 0.3% during the first quarter. State Street Corp now owns 1,050,160 shares of the company’s stock worth $51,469,000 after purchasing an additional 2,913 shares during the last quarter. Vanguard Group Inc. lifted its stake in LivaNova PLC by 4.5% during the first quarter. Vanguard Group Inc. now owns 777,356 shares of the company’s stock worth $38,098,000 after purchasing an additional 33,645 shares during the last quarter. Finally, Credit Suisse AG lifted its stake in LivaNova PLC by 2,084.7% during the first quarter. Credit Suisse AG now owns 694,275 shares of the company’s stock worth $34,026,000 after purchasing an additional 662,496 shares during the last quarter. 82.36% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Marshall Wace North America L.P. Purchases Shares of 41,269 LivaNova PLC (LIVN)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/04/marshall-wace-north-america-l-p-purchases-shares-of-41269-livanova-plc-livn.html.

A number of equities research analysts have recently weighed in on the company. Berenberg Bank reissued a “buy” rating and issued a $70.00 target price on shares of LivaNova PLC in a research note on Friday, August 11th. BidaskClub lowered LivaNova PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. WBB Securities lowered LivaNova PLC from a “hold” rating to a “sell” rating and set a $50.00 target price for the company. in a research note on Tuesday, August 15th. Finally, Needham & Company LLC assumed coverage on LivaNova PLC in a research note on Wednesday, August 23rd. They issued a “hold” rating for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $58.00.

In related news, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova PLC stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $60.76, for a total value of $60,760.00. Following the completion of the transaction, the director now owns 58,296 shares in the company, valued at $3,542,064.96. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 3,000 shares of company stock valued at $183,110. 0.28% of the stock is currently owned by company insiders.

Shares of LivaNova PLC (LIVN) opened at 63.66 on Monday. The company has a market cap of $3.11 billion, a price-to-earnings ratio of 113.68 and a beta of 0.58. The stock has a 50 day moving average price of $61.60 and a 200-day moving average price of $56.54. LivaNova PLC has a 1-year low of $40.83 and a 1-year high of $64.95.

LivaNova PLC (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.19. The company had revenue of $321.40 million during the quarter, compared to analyst estimates of $315.75 million. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. The company’s quarterly revenue was up .1% on a year-over-year basis. Equities research analysts forecast that LivaNova PLC will post $3.22 earnings per share for the current year.

LivaNova PLC Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).

Institutional Ownership by Quarter for LivaNova PLC (NASDAQ:LIVN)

Receive News & Stock Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related stocks with our FREE daily email newsletter.